Recombinant hemagglutinin influenza vaccine provides broader spectrum protection

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

(2015) Ruvim Izikson et al.   VACCINE

Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines

(2015) Ernest Milián et al.   Biomed Research International

Pandemic Preparedness and Response — Lessons from the H1N1 Influenza of 2009

(2014) Harvey V. Fineberg   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

(2014) Carlos A. DiazGranados et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses

(2014) Danuta M. Skowronski et al.   PLoS One

Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections

(2014) J.-R. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Influenza virus hemagglutinin stalk-based antibodies and vaccines

(2013) Florian Krammer et al.   Current Opinion in Virology

Estimates of Influenza Vaccine Effectiveness for 2007–2008 From Canada's Sentinel Surveillance System: Cross-Protection Against Major and Minor Variants

(2012) Naveed Z. Janjua et al.   JOURNAL OF INFECTIOUS DISEASES

Influenza viral neuraminidase: the forgotten antigen

(2011) Bert E Johansson et al.   Expert Review of Vaccines

A fast track influenza virus vaccine produced in insect cells

(2011) Manon M.J. Cox et al.   JOURNAL OF INVERTEBRATE PATHOLOGY

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆

(2011) R. Baxter et al.   VACCINE

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial

(2011) John J. Treanor et al.   VACCINE

Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the United States (April 2009-April 2010)

(2010) S. S. Shrestha et al.   CLINICAL INFECTIOUS DISEASES

Glycans on influenza hemagglutinin affect receptor binding and immune response

(2009) C.-C. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old

(2009) W.A. Keitel et al.   VACCINE